Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 18;4(4):100600.
doi: 10.1016/j.gastha.2024.100600. eCollection 2025.

Iodine-131 Combined With Plasma Exchange Treatment in Graves' Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20

Affiliations

Iodine-131 Combined With Plasma Exchange Treatment in Graves' Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20

Xin-Fang Zhu et al. Gastro Hep Adv. .

Abstract

Background and aims: The purpose of this retrospective study is to describe the Graves' hyperthyroidism patients with severe liver injury treated by iodine-131 combined with plasma exchange (PE).

Methods: The patients who had hyperthyroidism caused by Graves' disease, with severe liver injury (The level of total bilirubin ≥12 mg/dL), and after 1 week of liver protective medication treatment, the patient's liver function did not improve, were enrolled in this study. All patients were treated with iodine-131 and PE. The patients' laboratory data after 3 months of isotope therapy were collected.

Results: In this study, there were 8 patients included, the average model for end-stage liver disease (MELD) scores were greater than 20 (ranges from 19 to 30) at baseline. The levels of hemoglobin, platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase, glutamyl transpeptidase, MELD scores, free triiodothyronine, free thyroxine, antithyroid peroxidase autoantibody and serum thyrotropin receptor antibodies after PE treatment were significantly lower than before PE treatment (P < .05). The level of total bilirubin at 3 months post-131I treatment was significantly lower than pre-131I treatment (P = .0200), the same was the level of direct bilirubin (P = .0200).

Conclusion: Our study enrolled Graves' hyperthyroidism patients with severe liver injury whose average MELD scores were greater than 20, and shows that liver function test can recover on about 3 months treated iodine-131 combined with PE therapy.

Keywords: Graves’ Disease; Isotope I131 Therapy; Liver Failure; Plasma Exchange.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The treatment process diagram of the patients.
Figure 2
Figure 2
Changes clinical characteristics before and after PE treatment. Panel A: the level of white blood cell count before and after PE treatment. Panel B: the level of hemoglobin before and after PE treatment. Panel C: the level of platelet counts before and after PE treatment. Panel D: the level of FT3 before and after PE treatment. Panel E: the level of FT4 before and after PE treatment. Panel F: the level of TRAb before and after PE treatment.
Figure 3
Figure 3
The level of bilirubin before and after iodine-131 treatment. Panel A: the level of total bilirubin before and after iodine-131 treatment. Panel B: the level of direct bilirubin before and after iodine-131 treatment. ∗Statistically significant difference.

Similar articles

References

    1. De Leo S., Lee S.Y., Braverman L.E. Hyperthyroidism. Lancet. 2016;388:906–918. - PMC - PubMed
    1. Kahaly G.J. Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020;105:3704–3720. - PMC - PubMed
    1. Ross D.S., Burch H.B., Cooper D.S., et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–1421. - PubMed
    1. Connelly-Smith L., Alquist C.R., Aqui N.A., et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38:77–278. - PubMed
    1. Sarin S.K., Choudhury A., Sharma M.K., et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353–390. - PMC - PubMed

LinkOut - more resources